|
MechanismDMD gene modulators |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismDMD gene modulators |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismDMD gene modulators |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Phase I/II Study of DS-5141b: Open-label Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
This is a phase I/II study to evaluate the safety, tolerability, efficacy, and pharmacokinetic (PK) profile of DS-5141b in patients with Duchenne muscular dystrophy (DMD) amenable to exon 45 skipping and to determine the dosage for subsequent studies.
100 Clinical Results associated with Orphan Disease Treatment Institute Co., Ltd.
0 Patents (Medical) associated with Orphan Disease Treatment Institute Co., Ltd.
100 Deals associated with Orphan Disease Treatment Institute Co., Ltd.
100 Translational Medicine associated with Orphan Disease Treatment Institute Co., Ltd.